Combined Treatment of Photodynamic Therapy and Bevacizumab for Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
Korean Journal of Ophthalmology
;
: 231-237, 2011.
Article
in English
| WPRIM
| ID: wpr-125054
ABSTRACT
PURPOSE:
To evaluate the outcome of a combined photodynamic therapy and intravitreal injection of bevacizumab in choroidal neovascularization secondary to age-related macular degeneration.METHODS:
Photodynamic therapy (PDT) was administered to 28 eyes followed by 3 consecutive bevacizumab injections. Patients were followed-up for more than 12 months. At baseline, 1, 3, 6, and 12 months post PDT, visual acuity (VA) and central macular thickness were measured using optical coherence tomography.RESULTS:
The mean VA was significantly improved from logarithm of the minimal angle of resolution 0.86 at baseline to 0.69 at 1 month (p = 0.011), 0.63 at 3 months (p = 0.003), 0.64 at 6 months (p = 0.004) and 0.60 at 12 months (p < 0.001). Central macular thickness decreased significantly from 328.3 microm at baseline to 230.0 microm at 6 months and 229.9 microm at 1 year (p < 0.001). Reinjection mean number was 0.4 for 6 months and 0.8 for 12 months. By 1 year, retreatment was performed in 10 eyes (36%).CONCLUSIONS:
PDT combined with three consecutive intraviteal bevacizumab injections was effective in improving VA and reducing central macular thickness.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Photochemotherapy
/
Porphyrins
/
Fluorescein Angiography
/
Visual Acuity
/
Retrospective Studies
/
Follow-Up Studies
/
Treatment Outcome
/
Photosensitizing Agents
/
Choroidal Neovascularization
/
Angiogenesis Inhibitors
Type of study:
Observational study
/
Prognostic study
/
Risk factors
Limits:
Aged
/
Female
/
Humans
/
Male
Language:
English
Journal:
Korean Journal of Ophthalmology
Year:
2011
Type:
Article
Similar
MEDLINE
...
LILACS
LIS